Profile data is unavailable for this security.
About the company
Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.
- Revenue in AUD (TTM)8.69m
- Net income in AUD-129.46m
- Incorporated2004
- Employees73.00
- LocationMesoblast LtdL 38 55 Collins StMELBOURNE 3000AustraliaAUS
- Phone+61 39639-6036
- Fax+61 39639-6030
- Websitehttps://www.mesoblast.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Imugene Ltd | 0.00 | -149.68m | 364.43m | 0.00 | -- | 3.03 | -- | -- | -0.0211 | -0.0211 | 0.00 | 0.0162 | 0.00 | -- | -- | -- | -85.91 | -44.42 | -95.62 | -47.46 | -- | -- | -- | -- | -- | -- | 0.0053 | -- | -- | -- | -294.78 | -- | 136.28 | -- |
Immutep Ltd | 119.62k | -42.72m | 458.19m | 19.00 | -- | 2.44 | -- | 3,830.37 | -0.0353 | -0.0353 | 0.0001 | 0.1293 | 0.0007 | -- | 0.655 | -- | -24.48 | -31.68 | -25.99 | -33.91 | -- | -- | -35,710.27 | -1,829.94 | -- | -- | 0.0083 | -- | -37.61 | -54.35 | -7.07 | -- | 86.40 | -- |
PYC Therapeutics Ltd | 22.86m | -37.73m | 793.23m | 23.00 | -- | 9.97 | -- | 34.71 | -0.0094 | -0.0094 | 0.0057 | 0.017 | 0.356 | -- | 97.03 | -- | -59.36 | -45.92 | -69.52 | -52.18 | -- | -- | -166.75 | -167.45 | -- | -69.18 | 0.0135 | -- | 43.85 | 882.22 | -65.54 | -- | -7.67 | -- |
Opthea Ltd | 183.50k | -324.17m | 1.10bn | 5.00 | -- | -- | -- | 6,004.50 | -0.5085 | -0.5085 | 0.0003 | -0.1022 | 0.0009 | -- | 0.0136 | -- | -153.25 | -112.75 | -215.25 | -134.33 | 100.00 | -- | -176,660.10 | -113,428.10 | -- | -5.08 | 1.61 | -- | 15.00 | 1.86 | -54.53 | -- | 20.99 | -- |
Mesoblast Ltd | 8.69m | -129.46m | 1.72bn | 73.00 | -- | 2.44 | -- | 198.47 | -0.129 | -0.129 | 0.0088 | 0.6195 | 0.0088 | -- | 3.21 | 119,001.30 | -13.14 | -12.62 | -14.38 | -13.97 | -166.30 | -109.14 | -1,490.28 | -692.63 | -- | -3.54 | 0.1984 | -- | -21.32 | -18.80 | -7.41 | -- | -0.5802 | -- |
Clarity Pharmaceuticals Ltd | 0.00 | -42.32m | 2.52bn | -- | -- | 16.81 | -- | -- | -0.1541 | -0.1541 | 0.00 | 0.4694 | 0.00 | -- | -- | -- | -36.56 | -- | -39.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -72.03 | -- | -- | -- |
Telix Pharmaceuticals Ltd | 645.68m | 49.19m | 6.86bn | 234.00 | 136.87 | 16.95 | 121.52 | 10.62 | 0.1497 | 0.1497 | 1.96 | 1.21 | 1.22 | 11.36 | 8.61 | -- | 9.31 | -29.08 | 15.01 | -40.27 | 61.80 | 61.64 | 7.62 | -37.14 | 0.8687 | -- | 0.052 | -- | 213.90 | 381.02 | 105.01 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 04 Jul 2024 | 36.43m | 3.19% |
M&G Investment Management Ltd.as of 31 Aug 2023 | 27.50m | 2.41% |
Thorney Investment Group Australia Pty Ltd.as of 22 Sep 2023 | 21.09m | 1.85% |
Vanguard Investments Australia Ltd.as of 30 Jun 2024 | 13.43m | 1.18% |
Independent Asset Management Pty Ltd.as of 22 Sep 2023 | 8.00m | 0.70% |
Dimensional Fund Advisors LPas of 30 Jun 2024 | 5.22m | 0.46% |
DFA Australia Ltd.as of 30 Jun 2024 | 4.79m | 0.42% |
Norges Bank Investment Managementas of 31 Dec 2023 | 2.76m | 0.24% |
BlackRock Asset Management North Asia Ltd.as of 30 Apr 2024 | 2.62m | 0.23% |
Charles Schwab Investment Management, Inc.as of 03 Jul 2024 | 2.03m | 0.18% |